Extending existing work on treatment effect heterogeneity with GLP-1RAs in this way to encompass enhanced predictive biomarkers, the newest GLP-1–associated agents, and broader clinical outcomes may offer the potential for a comprehensive precision medicine approach to GLP-1RA therapy to optimize treatment and meaningfully improve the clinical care of people with T2D. Here, GLP1R is linked to type 2 diabetes mellitus.